Ruby Gillis

Ruby Gillis serves as a Researcher within the Department of General Practice at Erasmus MC, focusing on neurological care for vulnerable patient populations with intellectual disabilities.

Her research program centers on anti-epileptic pharmacotherapy, specifically investigating brivaracetam and levetiracetam for epilepsy management in intellectually impaired individuals. Key research dimensions include drug tolerability assessment, side effect profiling (particularly somnolence), and clinical trial methodology tailored to this patient cohort. The 2021 publication in Acta Neurologica Belgica represents her primary scholarly contribution, demonstrating methodical analysis of treatment efficacy within a specialized clinical context.

While currently limited to a single high-impact publication with significant citation metrics (12 Scopus citations) and policy relevance, her work establishes a specialized niche in neuropharmacology for cognitively impaired epilepsy patients, highlighting translational research potential for improved therapeutic protocols.